Comprehensive medication guide to Veltassa including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0/month for eligible commercially insured patients enrolled in Vifor Pharma's co-pay savings program; otherwise $30–$150 copay depending on plan tier. Most plans classify Veltassa as Tier 3 or specialty; prior authorization is commonly required.
Estimated Cash Pricing
$1,200–$1,500 retail for a 30-day supply (30 packets of 8.4g); as low as $977 with SingleCare or GoodRx discount coupons at participating pharmacies. No generic is currently available.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Veltassa is the brand name for patiromer sorbitex calcium, an FDA-approved prescription medication used to treat hyperkalemia — dangerously elevated levels of potassium in the blood. Approved in October 2015, it was the first new potassium-binding medication approved in over 50 years. Veltassa is manufactured by Vifor Pharma, Inc. and is available only as a brand-name drug (no generic is currently available).
Veltassa is an off-white powder that comes in single-use packets. Patients mix it with water, juice, or soft food (like applesauce, yogurt, or pudding) and drink it once daily. It works entirely within the gastrointestinal tract — it is not absorbed into the bloodstream, making it uniquely safe for long-term use.
Hyperkalemia most commonly affects patients with chronic kidney disease (CKD), heart failure, or type 2 diabetes — especially those on ACE inhibitors, ARBs, or potassium-sparing diuretics like spironolactone. Veltassa helps these patients maintain potassium in a safe range while continuing life-protecting RAAS inhibitor therapy.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Veltassa (patiromer) is a non-absorbed cation exchange polymer. After swallowing, it travels through the stomach and small intestine until it reaches the colon. In the colon, Veltassa releases calcium ions from its polymer structure and captures free potassium ions — a process called cation exchange. The potassium becomes bound to the patiromer polymer and can no longer be absorbed back into the bloodstream.
Because the polymer is not absorbed, it passes out of the body through the stool — taking the bound potassium with it. This removes excess potassium from the body without affecting other organ systems. Veltassa begins lowering serum potassium approximately 7 hours after the first dose, with maximum effect at 48 hours. This delayed onset makes Veltassa a maintenance medication, not an emergency treatment.
As a side effect of the exchange process, Veltassa also binds some magnesium in the colon, which can lower blood magnesium levels (hypomagnesemia) in some patients. Regular monitoring of serum magnesium is recommended, and supplementation may be needed.
1 gram — powder packet for oral suspension
Starter/pediatric dose unit
8.4 grams — powder packet for oral suspension
Standard adult starting dose; one packet per day
16.8 grams — powder packet for oral suspension
Mid-range maintenance dose
25.2 grams — powder packet for oral suspension
Maximum daily dose for adults
Veltassa is not listed on the FDA's official drug shortage list as of 2026, but many patients report significant difficulty finding it at standard retail pharmacies. As a brand-only specialty medication with refrigeration requirements and a retail price over $1,200 per month, smaller and independent pharmacies often choose not to stock it due to low turnover and cold storage costs.
Patients are most likely to find Veltassa in stock at large chain pharmacies near hospitals or dialysis centers, specialty pharmacies, and hospital outpatient pharmacies. Mail-order pharmacies are also a reliable option for long-term supplies. If you're struggling to locate Veltassa, medfinder calls local pharmacies on your behalf to find which ones have it in stock and texts you the results.
Insurance prior authorization is another major barrier. Most commercial and Medicare Part D plans require PA before covering Veltassa, which can delay access by days or weeks. Plan ahead by refilling 7–10 days early and ensuring your insurance approval is current.
Veltassa (patiromer) is not a controlled substance, so any licensed prescriber can prescribe it without special DEA registration. Prescriptions can be written by physicians, nurse practitioners, and physician assistants in all states. A valid prescription is required — it cannot be purchased over the counter.
Veltassa is most commonly prescribed by specialists who treat the underlying conditions causing hyperkalemia:
Nephrologists — kidney specialists are the most common Veltassa prescribers; CKD is the leading cause of chronic hyperkalemia
Cardiologists — heart failure patients on RAAS inhibitors frequently develop hyperkalemia
Primary care physicians and internists — can diagnose and manage mild-to-moderate hyperkalemia directly
Endocrinologists — may prescribe for diabetic patients on RAAS-inhibiting medications
Nurse practitioners and physician assistants — can independently prescribe Veltassa in most states
Telehealth prescribing is available for Veltassa. Since it is not a controlled substance, telehealth providers can prescribe it without additional restrictions. Patients will typically need to provide recent lab results (serum potassium levels) before a telehealth visit. Platforms like Teladoc, MDLive, and Sesame offer relevant specialist consultations.
No. Veltassa (patiromer) is not a controlled substance and has no DEA schedule. It can be prescribed by any licensed healthcare provider — including physicians, nurse practitioners, and physician assistants — without special DEA registration or prescribing authority. Prescriptions for Veltassa can be refilled without the strict limitations that apply to controlled drugs.
Veltassa is a prescription-only medication, which means it cannot be purchased over the counter. A valid prescription from a licensed provider is required. Because it is not a controlled substance, telehealth providers can also prescribe Veltassa for established patients with documented hyperkalemia and current lab results.
Most side effects of Veltassa are mild to moderate and gastrointestinal in nature. Common side effects (occurring in 2% or more of patients in clinical trials) include:
Constipation (most common; usually mild and resolves over time)
Hypomagnesemia (low magnesium — 5.3% of patients in trials; requires monitoring)
Diarrhea
Nausea
Abdominal discomfort or pain
Flatulence
Severe hypomagnesemia: Dizziness, irregular heartbeat, muscle cramps or spasms, jitteriness, choking/coughing — call your doctor immediately
Severe allergic reaction: Hives, difficulty breathing, swelling of face/lips/tongue/throat — seek emergency care immediately
Severe constipation or bowel obstruction: Stop Veltassa and call your doctor if unable to pass stool, severe abdominal pain, or vomiting occurs
Know what you need? Skip the search.
Lokelma (sodium zirconium cyclosilicate)
FDA-approved 2018. Faster onset (~1 hour vs ~7 hours). Contains sodium — may cause edema, not ideal for heart failure patients. Preferred in hospital settings. Requires 2-hour medication separation.
Sodium Polystyrene Sulfonate (SPS/Kayexalate generic)
Oldest potassium binder (FDA-approved 1958). Generic available, significantly cheaper (under $50/month). Less predictable, more GI side effects. Contains sodium. Generally used as short-term bridge only.
Dietary Potassium Restriction
Low-potassium diet (limiting bananas, tomatoes, potatoes, legumes, salt substitutes). Used as adjunct to medication therapy; rarely sufficient alone for significant hyperkalemia.
Prefer Veltassa? We can find it.
Ciprofloxacin
majorClinically significant binding confirmed in vivo. Separate by at least 3 hours before or after Veltassa.
Levothyroxine (Synthroid)
majorSignificant binding confirmed. Take thyroid medication at least 3 hours separate from Veltassa to avoid reduced thyroid drug absorption.
Metformin (Glucophage)
majorBinding confirmed. Common co-prescription in CKD/diabetes patients. Separate by 3 hours.
Quinidine
majorClinically significant binding confirmed. Separate by 3 hours.
Delafloxacin
majorBinding confirmed. Separate by 3 hours.
ACE Inhibitors (lisinopril, enalapril, ramipril, etc.)
moderateMust be separated by 3 hours. These are among the most common co-medications in Veltassa patients.
ARBs (losartan, valsartan, candesartan, etc.)
moderateMust be separated by 3 hours. Common co-medications in CKD and heart failure patients.
Proton Pump Inhibitors (omeprazole, dexlansoprazole)
moderatePPIs can independently lower magnesium levels; additive risk of hypomagnesemia when combined with Veltassa. Monitor magnesium more closely.
Lamivudine oral solution
moderateSorbitol counterion in Veltassa may reduce lamivudine bioavailability. Consider tablet formulation instead of oral solution.
Veltassa (patiromer) is an important advance in the management of chronic hyperkalemia — a condition that has historically been difficult to treat long-term without compromising essential RAAS inhibitor therapy. For patients with CKD, heart failure, and diabetes, Veltassa enables continuation of kidney- and heart-protective medications that would otherwise have to be dose-reduced or stopped entirely due to rising potassium.
The main challenges with Veltassa in 2026 are access and cost. As a brand-only specialty drug requiring refrigeration, it is not universally available at retail pharmacies, and prior authorization hurdles can delay therapy. Commercially insured patients should enroll in the Vifor Pharma co-pay program (potentially $0/month). Medicare and uninsured patients should explore the PAN Foundation and manufacturer free drug program.
If you are struggling to find Veltassa at a pharmacy near you, medfinder can help — we call pharmacies in your area to locate which ones have your medication in stock and text you the results, saving you hours of frustration.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini